101. Increased Seroprevalence and Improved Antibody Responses Following Third Primary SARS-CoV-2 Immunisation: An Update From the COV-AD Study
- Author
-
Adrian M. Shields, Sian E. Faustini, Harriet J. Hill, Saly Al-Taei, Chloe Tanner, Fiona Ashford, Sarita Workman, Fernando Moreira, Nisha Verma, Hollie Wagg, Gail Heritage, Naomi Campton, Zania Stamataki, Mark T. Drayson, Paul Klenerman, James E. D. Thaventhiran, Shuayb Elkhalifa, Sarah Goddard, Sarah Johnston, Aarnoud Huissoon, Claire Bethune, Suzanne Elcombe, David M. Lowe, Smita Y. Patel, Sinisa Savic, Alex G. Richter, Siobhan O. Burns, the COV-AD consortium, Zahra Ahmed, Angus Best, Joanne Dasgin, Mohammad Dinally, Elena Efstathiou, Theresa McCarthy, Madeeha Hoque, Shannon Page, Timothy Plant, Zehra Suleiman, Neil Townsend, Charlotte Trinham, Sinead Walder, Hollie Bancroft, Michelle Bates, Hayley Clifford, Christopher McGee, Samuel Chee, Lucy Common, Archana Herwadkar, Karen Knowles, Maria Poulaka, Georgina Davis, Daniel Mullan, Stuart Wareham, Fatima Dhalla, Rashmi Jain, Hadeil Morsi, Nicholas Peters, Mark Gompels, Malgorzata Slowinsksa, Dan Hartland, Emily Heritage, Joe Humphreys, Deborah Hughes, Ann Ivory, Sinead Kelly, Eileen O’Grady, and Archana Shajidevadas
- Subjects
COVID-19 ,CVID ,inborn errors of immunity ,primary immunodeficiency ,secondary immunodeficiency ,vaccination ,Immunologic diseases. Allergy ,RC581-607 - Abstract
BackgroundPatients with primary and secondary antibody deficiency are vulnerable to COVID-19 and demonstrate diminished responses following two-dose SARS-CoV-2 vaccine schedules. Third primary vaccinations have been deployed to enhance their humoral and cellular immunity.ObjectivesTo determine the immunogenicity of the third primary SARS-CoV-2 immunisation in a heterogeneous cohort of patients with antibody deficiency.MethodsParticipants enrolled in the COV-AD study were sampled before and after their third vaccine dose. Serological and cellular responses were determined using ELISA, live-virus neutralisation and ELISPOT assays.ResultsFollowing a two-dose schedule, 100% of healthy controls mounted a serological response to SARS-CoV-2 vaccination, however, 38.6% of individuals with antibody deficiency remained seronegative. A third primary SARS-CoV-2 vaccine significantly increased anti-spike glycoprotein antibody seroprevalence from 61.4% to 76.0%, the magnitude of the antibody response, its neutralising capacity and induced seroconversion in individuals who were seronegative after two vaccine doses. Vaccine-induced serological responses were broadly cross-reactive against the SARS-CoV-2 B.1.1.529 variant of concern, however, seroprevalence and antibody levels remained significantly lower than healthy controls. No differences in serological responses were observed between individuals who received AstraZeneca ChAdOx1 nCoV-19 and Pfizer BioNTech 162b2 during their initial two-dose vaccine schedule. SARS-CoV-2 infection-naive participants who had received a heterologous vaccine as a third dose were significantly more likely to have a detectable T cell response following their third vaccine dose (61.5% vs 11.1%).ConclusionThese data support the widespread use of third primary immunisations to enhance humoral immunity against SARS-CoV-2 in individuals with antibody deficiency.
- Published
- 2022
- Full Text
- View/download PDF